BioLineRx Ltd. Q2 FY2025 earnings call

• Ongoing search for early-stage oncology and rare disease assets, targeting transaction this year.
• Transformational out-licensing agreement with Ayrmid for APHEXDA, retaining rights for solid tumors like PDAC.
• APHEXDA in stem cell mobilization and sickle cell disease trials; CheMo4METPANC trial for PDAC with Regeneron collaboration.
• ASCO data from PDAC trial showed positive results, including increased CD8-positive T cell density and long-term progression-free patients.
• Streamlined organization and strengthened balance sheet after restructuring, with cash runway extended.

Total revenues for the second quarter of 2025 were $0.3 million, consisting of royalties from Ayrmid for APHEXDA commercialization. Cost of revenues was immaterial. Research and development expenses were $2.3 million. Sales and marketing expenses were $0. General and administrative expenses were $0.2 million. Net loss was $3.9 million. Cash and equivalents as of June 30, 2025, were $28.2 million, sufficient to fund operations into the first half of 2027.

• Targeting closure of transaction for early-stage assets this year.
• Cash and equivalents of $28.2 million provide funding runway into first half of 2027.

• Risks associated with forward-looking statements differing from actual results.
• Lengthy and intensive due diligence process for evaluating new assets, including verification of preclinical data, IP, and manufacturing processes.

Q: About CheMo4METPANC study rights and data timing A: No options or rights of first look for Regeneron; interim analysis is prespecified, timing to be discussed with Columbia regarding publication.

Q: ASCO data feedback A: Excitement about results, especially reduction in liver metastases Q: Sources of new assets A: Smaller companies, both private and public, as best source due to funding environment and transactability, fitting early clinical stage wheelhouse